Cel Sci (CVM) Other Operating Expenses (2010 - 2022)
Cel Sci (CVM) posted Other Operating Expenses of -$50171.0 for Q4 2022, up 99.29% sequentially from -$7.1 million in Q3 2019.
Cel Sci (CVM) Other Operating Expenses (2010 - 2022) Analysis & Trends
Cel Sci has reported Other Operating Expenses for 8 years, with the latest figure at -$50171.0 in Q4 2022.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$50171.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$50171.0 (changed N/A YoY) and the FY2014 annual result came in at $1182.0, down 72.83% from the prior year.
- Other Operating Expenses climbed to -$50171.0 in Q4 2022 per CVM's latest filing, from -$7.1 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$50171.0 in Q4 2022 and troughed at -$7.1 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -50,171.00 |
| Sep 30, 2019 | -7.07 Mn |
| Dec 31, 2015 | -115.00 |
| Sep 30, 2015 | 313.00 |
| Dec 31, 2014 | -313.00 |
| Sep 30, 2014 | 1,182.00 |
| Jun 30, 2014 | -240.00 |
| Mar 31, 2014 | 480.00 |
| Dec 31, 2013 | -240.00 |
| Sep 30, 2013 | 151.00 |
| Jun 30, 2013 | -6,452.00 |
| Mar 31, 2013 | 428.00 |
| Dec 31, 2012 | 10,223.00 |
| Sep 30, 2012 | -27,953.00 |
| Jun 30, 2012 | 109,718.00 |
| Mar 31, 2012 | 2.74 Mn |
| Dec 31, 2011 | 138,425.00 |
| Sep 30, 2011 | 96,880.00 |
| Jun 30, 2011 | 148,148.00 |
| Mar 31, 2011 | 145,141.00 |